Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Margolin, K' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 62 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Atkins, MB; Dutcher, J; Weiss, G; Margolin, K; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
      Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials

      MEDICAL ONCOLOGY
    2. Dutcher, J; Atkins, MB; Margolin, K; Weiss, G; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
      Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines

      MEDICAL ONCOLOGY
    3. Margolin, K; Synold, T; Longmate, J; Doroshow, JH
      Methodologic guidelines for the design of high-dose chemotherapy regimens

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    4. Somlo, G; Chow, W; Hamasaki, V; Leong, L; Margolin, K; Morgan, R; Sniecinski, I; Frankel, P; Reardon, D; Longmate, J; Raschko, J; Shibata, S; O'Donnell, M; Smith, E; Tetef, M; Forman, S; Yen, Y; Molina, A; Doroshow, JH
      Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    5. Tetef, ML; Synold, TW; Chow, W; Leong, L; Margolin, K; Morgan, R; Raschko, J; Shibata, S; Somlo, G; Yen, Y; Groshen, S; Johnson, K; Lenz, HJ; Gandara, D; Doroshow, JH
      Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies

      CLINICAL CANCER RESEARCH
    6. Gordon, MS; Margolin, K; Talpaz, M; Sledge, GW; Holmgren, E; Benjamin, R; Stalter, S; Shak, S; Adelman, DC
      Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

      JOURNAL OF CLINICAL ONCOLOGY
    7. Margolin, K; Gordon, MS; Holmgren, E; Gaudreault, J; Novotny, W; Fyfe, G; Adelman, D; Stalter, S; Breed, J
      Phase Ib trial of intravenous recombinant humanized monoclonal antibody tovascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data

      JOURNAL OF CLINICAL ONCOLOGY
    8. Lee, P; Wang, F; Kuniyoshi, J; Rubio, V; Stuges, T; Groshen, S; Gee, C; Lau, R; Jeffery, G; Margolin, K; Marty, V; Weber, J
      Effects of interleukin-12 on the immune response to a multipeptide vaccinefor resected metastatic melanoma

      JOURNAL OF CLINICAL ONCOLOGY
    9. Flaherty, LE; Atkins, M; Sosman, J; Weiss, G; Clark, JI; Margolin, K; Dutcher, J; Gordon, MS; Lotze, M; Mier, J; Sorokin, P; Fisher, RI; Appel, C; Du, W
      Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two phase II cytokineworking group trials

      JOURNAL OF CLINICAL ONCOLOGY
    10. Morgan, RJ; Synold, T; Carr, BI; Doroshow, JH; Womack, EP; Shibata, S; Somlo, G; Raschko, J; Leong, L; McNamara, M; Chow, W; Tetef, M; Margolin, K; Akman, S; Longmate, J
      Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    11. Morgan, RJ; Doroshow, JH; Leong, L; Schriber, J; Shibata, S; Forman, S; Hamasaki, V; Margolin, K; Somlo, G; Alvarnas, J; McNamara, M; Longmate, J; Raschko, J; Chow, W; Vasilev, S; McGonigle, K; Yen, Y
      Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

      BONE MARROW TRANSPLANTATION
    12. Margolin, K; Longmate, J; Synold, TW; Gandara, DR; Weber, J; Gonzalez, R; Johansen, MJ; Newman, R; Baratta, T; Doroshow, JH
      Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium

      INVESTIGATIONAL NEW DRUGS
    13. Snyder, DS; Nademanee, AP; O'Donnell, MR; Parker, PM; Stein, AS; Margolin, K; Somlo, G; Molina, A; Spielberger, R; Kashyap, A; Fung, H; Vora, N; Slovak, ML; Niland, J; Palmer, J; Negrin, RS; Amylon, MD; Blume, KG; Forman, SJ
      Allogeneic bone marrow transplantation for BCR-ABL positive acute lymphoblastic leukemia

      ACUTE LEUKEMIAS VIII: PROGNOSTIC FACTORS AND TREATMENT STRATEGIES
    14. Margolin, K; Forman, SJ
      Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    15. Dutcher, JP; Logan, T; Gordon, M; Sosman, J; Weiss, G; Margolin, K; Plasse, T; Mier, J; Lotze, M; Clark, J; Atkins, M
      Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group study

      CLINICAL CANCER RESEARCH
    16. Morgan, RJ; Braly, P; Leong, L; Shibata, S; Margolin, K; Somlo, G; McNamara, M; Longmate, J; Schinke, S; Raschko, J; Nagasawa, S; Kogut, N; Najera, L; Johnson, D; Doroshow, JH
      Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracilin previously treated patients with advanced ovarian cancer: Long-term follow-up

      GYNECOLOGIC ONCOLOGY
    17. Snyder, DS; Nademanee, AP; O'Donnell, MR; Parker, PM; Stein, AS; Margolin, K; Somlo, G; Molina, A; Spielberger, R; Kashyap, A; Fung, H; Slovak, ML; Dagis, A; Negrin, RS; Amylon, MD; Blume, KG; Forman, SJ
      Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

      LEUKEMIA
    18. Tetef, M; Leong, L; Ahn, C; Akman, S; Chow, W; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Doroshow, JH
      Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial

      CANCER INVESTIGATION
    19. Atkins, MB; Lotze, MT; Dutcher, JP; Fisher, RI; Weiss, G; Margolin, K; Abrams, J; Sznol, M; Parkinson, D; Hawkins, M; Paradise, C; Kunkel, L; Rosenberg, SA
      High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993

      JOURNAL OF CLINICAL ONCOLOGY
    20. Morgan, RJ; Braly, P; Cecchi, G; Leong, L; Shibata, S; Margolin, K; Somlo, G; McNamara, M; Longmate, J; Schinke, S; Raschko, J; Nagasawa, S; Kogut, N; Parker, P; Stein, A; Cho, J; Smith, E; Coluzzi, P; Najera, L; Johnson, D; Womack, E; Doroshow, JH
      Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up

      GYNECOLOGIC ONCOLOGY
    21. Somlo, G; Sniecinski, I; ter Veer, A; Longmate, J; Knutson, G; Vuk-Pavlovic, S; Bhatia, R; Chow, W; Leong, L; Morgan, R; Margolin, K; Raschko, J; Shibata, S; Tetef, M; Yen, Y; Forman, S; Jones, D; Ashby, M; Fyfe, G; Hellmann, S; Doroshow, JH
      Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy

      BLOOD
    22. MORGAN RJ; NEWMAN EM; DOROSHOW JH; MCGONIGLE K; MARGOLIN K; RASCHKO J; CHOW W; SOMLO G; LEONG L; TETEF M; SHIBATA S; HAMASAKI V; CARROLL M; VASILEV S; AKMAN S; COLUZZI P; WAGMAN L; LONGMATE J; PAZ B; YEN Y; KLEVECZ R
      PHASE-I TRIAL OF INTRAPERITONEAL IODODEOXYURIDINE WITH AND WITHOUT INTRAVENOUS HIGH-DOSE FOLINIC ACID IN THE TREATMENT OF ADVANCED MALIGNANCIES PRIMARILY CONFINED TO THE PERITONEAL-CAVITY - FLOW CYTOMETRIC ANDPHARMACOKINETIC ANALYSIS

      Cancer research
    23. DUTCHER JP; FISHER RI; WEISS G; ARONSON F; MARGOLIN K; LOUIE A; MIER J; CALIENDO G; SOSMAN JA; ECKARDT JR; ERNEST M; DOROSHOW J; ATKINS M
      OUTPATIENT SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA FOR METASTATIC RENAL-CELL CANCER - 5-YEAR FOLLOW-UP OF THE CYTOKINE WORKING GROUP-STUDY

      The cancer journal from Scientific American
    24. VANBESIEN K; MARGOLIN K; CHAMPLIN R; FORMAN S
      ACTIVITY OF INTERLEUKIN-2 IN NON-HODGKINS-LYMPHOMA FOLLOWING TRANSPLANTATION OF INTERLEUKIN-2-ACTIVATED AUTOLOGOUS BONE-MARROW OR STEM-CELLS

      The cancer journal from Scientific American
    25. DUTCHER JP; ATKINS M; FISHER R; WEISS G; MARGOLIN K; ARONSON F; SOSMAN J; LOTZE M; GORDON M; LOGAN T; MIER J
      INTERLEUKIN-2-BASED THERAPY FOR METASTATIC RENAL-CELL CANCER - THE CYTOKINE WORKING GROUP EXPERIENCE, 1989-1997

      The cancer journal from Scientific American
    26. MARGOLIN K; ATKINS M; SPARANO J; SOSMAN J; WEISS G; LOTZE M; DOROSHOW J; MIER J; OBOYLE K; FISHER R; CAMPBELL E; RUBIN J; FEDERIGHI D; BURSTEN S
      PROSPECTIVE RANDOMIZED TRIAL OF LISOFYLLINE FOR THE PREVENTION OF TOXICITIES OF HIGH-DOSE INTERLEUKIN-2 THERAPY IN ADVANCED RENAL-CANCER AND MALIGNANT-MELANOMA

      Clinical cancer research
    27. MORGAN RJ; DOROSHOW JH; VENKATARAMAN K; CHANG K; RASCHKO J; SOMLO G; LEONG L; TETEF M; SHIBATA S; HAMASAKI V; MARGOLIN K; FORMAN S; AKMAN S; COLUZZI P; AHN C; WEISS L; GADGIL U; HARRISON J
      HIGH-DOSE INFUSIONAL DOXORUBICIN AND CYCLOPHOSPHAMIDE - A FEASIBILITYSTUDY OF TANDEM HIGH-DOSE CHEMOTHERAPY CYCLES WITHOUT STEM-CELL SUPPORT

      Clinical cancer research
    28. SOMLO G; DOROSHOW JH; FORMAN SJ; ODOMMARYON T; LEE J; CHOW W; HAMASAKI V; LEONG L; MORGAN R; MARGOLIN K; RASCHKO J; SHIBATA S; TETEF M; YEN Y; SIMPSON J; MOLINA A
      HIGH-DOSE CHEMOTHERAPY AND STEM-CELL RESCUE IN THE TREATMENT OF HIGH-RISK BREAST-CANCER - PROGNOSTIC INDICATORS OF PROGRESSION-FREE AND OVERALL SURVIVAL

      Journal of clinical oncology
    29. STEIN A; ODONNELL MR; SLOVAK ML; LEE J; NADEMANEE A; PARKER P; SNYDER D; SMITH E; MOLINA A; SOMLO G; MARGOLIN K; FAHEY J; BIERMAN P; STEPAN D; NILAND J; BLUME KG; FORMAN SJ
      CYTOGENETICS PREDICT COMPLETE REMISSION RATE (CR) FOR ADULT PATIENTS WITH DE-NOVO ACUTE MYELOGENOUS LEUKEMIA (AML) TREATED WITH HIGH-DOSE CYTARABINE (HD ARA-C)

      Blood
    30. ODONNELL M; STEIN A; SNYDER DS; NADEMANEE A; PARKER PM; SMITH EP; MOLINA A; KASHYAP A; MARGOLIN K; SOMLO G; FORMAN SJ
      ALLOGENEIC MARROW TRANSPLANTATION - A CURATIVE OPTION FOR TREATMENT RELATED MYELODYSPLASIA (MDS)

      Blood
    31. STEIN A; ODONNELL MR; LEE J; BHATIA R; FUNG H; KASHYAP A; KRISHNAN A; NADEMANEE A; MOLINA A; MARGOLIN K; PARKER P; PLANAS I; SPIELBERGER R; SNYDER D; SMITH E; SOMLO G; SLOVAK ML; VORA N; SNIECINSKI I; NILAND J; FORMAN SJ
      PHASE-2 STUDY OF INTERLEUKIN-2 (IL-2) FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANT (ASCT) FOR ADULT PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) IN FIRST COMPLETE REMISSION (CR)

      Blood
    32. SOMLO G; SNYDER D; BROWN A; DAGIS A; NADEMANEE A; ODONNELL M; PARKER P; STEIN A; SMITH E; MOLINA A; SPIELBERGER R; MARGOLIN K; PLANAS I; KASHYAP A; CHOW W; FUNG H; BHATIA R; FORMAN SJ
      TANDEM CYCLE HIGH-DOSE CHEMOTHERAPY (HDCT) OF MELPHALAN (MEL) AND BUSULFAN CYCLOPHOSPHAMIDE (BU/CY) WITH PERIPHERAL-BLOOD PROGENITOR-CELL RESCUE (PBPC) IN MULTIPLE-MYELOMA (MM)/

      Blood
    33. WISEMAN GA; SOLINGER AM; GRILLOLOPEZ A; STABIN M; DUNN WL; WITZIG TE; SPIES S; GORDON L; RAUBITSCHEK A; MARGOLIN K; KARVELIS K; JANAKIRAMAN N; SILVERMAN DH; EMMANOULIDES C; ROYSTON I; CHINN P; PARKER E; CARTER W; WHITE CA
      IDEC-Y2B8 (Y-90 CONJUGATED ANTI-CD20) DOSIMETRY CALCULATED FROM IN-111 ANTI-CD20 IN PATIENTS WITH LOW AND INTERMEDIATE GRADE B-CELL NON-HODGKINS-LYMPHOMA (NHL) EMPHASIS ON BONE-MARROW (BM)

      Blood
    34. SOMLO G; SNIECINSKI I; BRENT J; TERVEER A; CHOW W; FORMAN S; HAMASAKI V; LEONG L; MORGAN R; MARGOLIN K; RADER D; RASCHKO J; SHIBATA S; TETEF M; YEN Y; MOLINA A; ASHBY M; JONES D; DOROSHOW JH
      RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN COMBINATION WITH G-CSF ISSAFE AND EFFECTIVE AS PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) MOBILIZER

      Blood
    35. FUNG H; NADEMANEE A; KASHYAP A; MOLINA A; ODONNELL M; SNYDER D; PARKER P; STEIN A; PLANAS I; SPIELBERGER R; KRISHNAN A; BHATIA R; MARGOLIN K; SOMLO G; CHOW W; DAGIS A; NILAND J; PEZNER R; FORMAN SJ
      EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS (PTS) WITH HODGKIN-DISEASE (HD) IN FIRST RELAPSE (REL) TREATED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) - DURATION OF FIRST REMISSION DOES NOT PREDICT THE TRANSPLANT OUTCOME

      Blood
    36. NADEMANEE A; MOLINA A; ODONNELL MR; DAGIS A; SNYDER DS; PARKER P; STEIN A; SMITH E; PLANAS I; KASHYAP A; SPIELBERGER R; FUNG H; WONG KK; SOMLO G; MARGOLIN K; CHOW W; SNIECINSKI I; VORA N; BLUME KG; NILAND J; FORMAN SJ
      RESULTS OF HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW STEM-CELL TRANSPLANTATION DURING REMISSION IN POOR-RISK INTERMEDIATE-GRADE AND HIGH-GRADE LYMPHOMA - INTERNATIONAL INDEX HIGH AND HIGH-INTERMEDIATE RISK GROUP

      Blood
    37. SOMLO G; SNIECINSKI I; ODOMMARYON T; NOWICKI B; CHOW W; HAMASAKI V; LEONG L; MARGOLIN K; MORGAN R; RASCHKO J; SHIBATA S; TETEF M; MOLINA A; BERENSON RJ; FORMAN SJ; DOROSHOW JH
      EFFECT OF CD34(-CELL REINFUSION AND GRANULOCYTE-COLONY-STIMULATING FACTOR PRIMING ON HEMATOPOIETIC RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY FOR BREAST-CANCER() SELECTION AND VARIOUS SCHEDULES OF STEM)

      Blood
    38. MARGOLIN K; DOROSHOW JH; AHN C; HAMASAKI V; LEONG L; MORGAN R; RASCHKO J; SHIBATA S; SOMLO G; TETEF M
      TREATMENT OF GERM-CELL CANCER WITH 2 CYCLES OF HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE WITH AUTOLOGOUS STEM-CELL SUPPORT

      Journal of clinical oncology
    39. BUDD GT; SAMUELS B; GOCKERMAN J; BAKER L; MARGOLIN K; ZALUPSKI M; FELSER J; JOHNSON B; ISAACS R; BUKOWSKI RM
      RANDOMIZED TRIAL OF MAID (MESNA, ADRIAMYCIN, IFOSFAMIDE, DECARBAZINE)CHEMOTHERAPY WITH G-CSF ALONE OR WITH G-CSF PLUS VARYING DOSES OF INTERLEUKIN-6 (IL-6)

      Blood
    40. PARKER PM; KASHYAP A; SPIELBERGER R; SNIECZINSKI I; CHOW W; FUNG H; MARGOLIN K; MOLINA A; NADEMANEE A; ODONNELL M; PLANAS I; SMITH E; SNYDER DS; SOMLO G; STEIN A; FORMAN SJ
      IMPROVED CR RATE USING HIGH-DOSE MELPHALAN (HDM) PRE G-CSF-PRIMED DONOR LEUKOCYTE INFUSION (DLI) FOR 2ND ALLOGENEIC BMT - ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PROPHYLAXIS IS NECESSARY FOR PATIENTS AT RISK FOR HYPERACUTE GVHD

      Blood
    41. MOLINA A; NADEMANEE A; ODONNELL MR; SNYDER DS; STEIN AS; PARKER PM; SMITH EP; LEE J; PLANAS I; KASHYAP A; SPIELBERGER RT; MARGOLIN K; SOMLO G; KAPOOR N; CHOW W; VORA N; SNIECINSKI I; NILAND J; FORMAN SJ
      HIGH-DOSE CHEMO RADIOTHERAPY (HDT) AND G-CSF PRIMED PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION (PBSCT) IN FOLLICULAR LOW-GRADE (FLGL) AND TRANSFORMED (TL) LYMPHOMA/

      Blood
    42. STEIN AS; ODONNELL MR; SLOVAK M; LEE J; KASHYAP A; MOLINA A; NADEMANEE A; PARKER P; PLANAS I; SNYDER DS; SPIELBERGER R; SOMLO G; MARGOLIN K; NILAND J; FORMAN SJ
      DO CYTOGENETICS PREDICT OUTCOME OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) FOR ACUTE MYELOGENOUS LEUKEMIA (AML) IN 1ST REMISSION (CR)

      Blood
    43. MOLINA A; PARKER P; STEIN AS; SPIELBERGER R; NADEMANEE A; SNYDER DS; ODONNELL MR; SMITH EP; MARGOLIN K; DAGIS A; PLANAS I; KASHYAP A; SOMLO G; KAPOOR N; VORA N; NILAND J; FORMAN SJ
      ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IN PATIENTS (PTS) WITH INCURABLE LOW-GRADE LYMPHOPROLIFERATIVE DISORDERS (LGLPD)

      Blood
    44. NADEMANEE A; MOLINA A; ODONNELL M; SNYDER DS; STEIN A; PARKER P; SMITH E; KASHYAP A; PLANAS I; SPIELBERGER R; FUNG H; SOMLO G; MARGOLIN K; CHOW W; VORA N; DAGIS A; NILAND J; BLUME KG; FORMAN SJ
      HIGH-DOSE THERAPY AND AUTOLOGOUS BONE-MARROW STEM-CELL TRANSPLANTATION (ABMT) AS CONSOLIDATION THERAPY DURING FIRST CR PR IN PATIENTS WITH POOR-RISK INTERMEDIATE-AND HIGH-GRADE LYMPHOMA/

      Blood
    45. TETEF M; DOROSHOW J; AKMAN S; COLUZZI P; LEONG L; MARGOLIN K; MORGAN RJ; RASCHKO J; SHIBATA S; SOMLO G; AHN C
      5-FLUOROURACIL AND HIGH-DOSE CALCIUM LEUCOVORIN FOR HEPATOCELLULAR-CARCINOMA - A PHASE-II TRIAL

      Cancer investigation
    46. MORGAN RJ; MARGOLIN K; RASCHKO J; AKMAN S; LEONG L; SOMLO G; SCANLON K; AHN C; CARROLL M; DOROSHOW JH
      PHASE-I TRIAL OF CARBOPLATIN AND INFUSIONAL CYCLOSPORINE IN ADVANCED MALIGNANCY

      Journal of clinical oncology
    47. TETEF M; MARGOLIN K; AHN C; AKMAN S; CHOW W; COLUZZI P; LEONG L; MORGAN RJ; RASCHKO J; SHIBATA S; SOMLO G; DOROSHOW JH
      MITOMYCIN-C AND MENADIONE FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL CANCERS - A PHASE-II TRIAL

      Journal of cancer research and clinical oncology
    48. TETEF M; MARGOLIN K; AHN C; AKMAN S; CHOW W; LEONG L; MORGAN RJ; RASCHKO J; SOMLO G; DOROSHOW JH
      MITOMYCIN-C AND MENADIONE FOR THE TREATMENT OF LUNG-CANCER - A PHASE-II TRIAL

      Investigational new drugs
    49. MORGAN RJ; SPEYER J; DOROSHOW JH; MARGOLIN K; RASCHKO J; SORICH J; AKMAN S; LEONG L; SOMLO G; VASILEV S; AHN C; JOHNSON D; BELLER U
      MODULATION OF 5-FLUOROURACIL WITH HIGH-DOSE LEUCOVORIN CALCIUM - ACTIVITY IN OVARIAN-CANCER AND CORRELATION WITH CA-125 LEVELS

      Gynecologic oncology
    50. PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ
      THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE

      Blood
    51. NADEMANEE A; SCHMIDT GM; PARKER P; DAGIS AC; STEIN A; SNYDER DS; ODONNELL M; SMITH EP; STEPAN DE; MOLINA A; WONG KK; MARGOLIN K; SOMLO G; LITTRELL B; WOO D; SNIECINSKI I; NILAND JC; FORMAN SJ
      THE OUTCOME OF MATCHED UNRELATED DONOR BONE-MARROW TRANSPLANTATION INPATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MOLECULAR TYPING FOR DONOR SELECTION AND GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS REGIMEN OF CYCLOSPORINE, METHOTREXATE, AND PREDNISONE

      Blood
    52. MARGOLIN K; VANBESIEN K; WRIGHT C; WOO D; CHAMPLIN R; THOMAS M; DAVIS M; GRIMM E; FORMAN S
      IMMUNOTHERAPY OF HEMATOLOGIC MALIGNANCIES WITH AUTOLOGOUS BONE-MARROWTRANSPLANT (ABMT) USING IN-VITRO INTERLEUKIN-2 (IL-2)-TREATED BONE-MARROW (BM)

      Blood
    53. STEIN AS; ODONNELL MR; NADEMANEE A; PARKER P; LEE J; MOLINA A; KASHYAP A; SPIELBERGER R; SMITH E; PLANAS I; SNYDER D; SOMLO G; MARGOLIN K; NILAND J; FORMAN SJ
      IDARUBICIN (IDA) AND HIGH-DOSE CYTOSINE-ARABINOSIDE (HD ARA-C) FOR INDUCTION THERAPY FOR AML AND AML ARISING FROM MYELODYSPLASIA (MDS AML)/

      Blood
    54. SPARANO JA; FISHER RI; WEISS GR; MARGOLIN K; ARONSON FR; HAWKINS MJ; ATKINS MB; DUTCHER JP; GAYNOR ER; BOLDT DH; DOROSHOW JH; ERNEST ML; SZNOL M; MIER JW
      PHASE-II TRIALS OF HIGH-DOSE INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS IN ADVANCED BREAST-CARCINOMA AND CARCINOMA OF THE LUNG, OVARY, AND PANCREAS AND OTHER TUMORS

      Journal of immunotherapy with emphasis on tumor immunology
    55. MARGOLIN K; ARONSON FR; SZNOL M; ATKINS MB; GUCALP R; FISHER RI; SUNDERLAND M; DOROSHOW JH; ERNEST ML; MIER JW; DUTCHER JP; GAYNOR ER; WEISS GR
      PHASE-II STUDIES OF RECOMBINANT HUMAN INTERLEUKIN-4 IN ADVANCED RENAL-CANCER AND MALIGNANT-MELANOMA

      Journal of immunotherapy with emphasis on tumor immunology
    56. SNYDER DS; NEGRIN RS; ODONNELL MR; CHAO NJ; AMYLON MD; LONG GD; NADEMANEE AP; STEIN AS; PARKER PM; SMITH EP; SOMLO G; MARGOLIN K; MOLINA A; STEPAN DE; LIPSETT JA; HOPPE RT; SLOVAK ML; NILAND JC; DAGIS AC; WONG RM; FORMAN SJ; BLUME KG
      FRACTIONATED TOTAL-BODY IRRADIATION AND HIGH-DOSE ETOPOSIDE AS A PREPARATORY REGIMEN FOR BONE-MARROW TRANSPLANTATION FOR 94 PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE

      Blood
    57. SWAMINATHAN N; VENKATARAMAN K; GADGIL U; MARGOLIN K
      POSSIBLE MECHANISM OF INTERLEUKIN-2-INDUCED DECLINE OF SERUM-CHOLESTEROL DURING ADOPTIVE CELLULAR IMMUNOTHERAPY IN CANCER-PATIENTS

      Biochemical medicine and metabolic biology
    58. SPARANO JA; FISHER RI; SUNDERLAND M; MARGOLIN K; ERNEST ML; SZNOL M; ATKINS MB; DUTCHER JP; MICETICH KC; WEISS GR; DOROSHOW JH; ARONSON FR; RUBINSTEIN LV; MIER JW
      RANDOMIZED PHASE-III TRIAL OF TREATMENT WITH HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON ALFA-2A IN PATIENTS WITH ADVANCED MELANOMA

      Journal of clinical oncology
    59. DUNST MN; MARGOLIN K; HORAK D
      LIDOCAINE FOR SEVERE HICCUPS

      The New England journal of medicine
    60. NADEMANEE A; SCHMIDT GM; LITTRELL B; NILAND JC; PARKER PM; ODONNELL MR; SNYDER DS; STEIN A; SMITH E; MOLINA A; WONG KK; MARGOLIN K; FORMAN SJ
      THE OUTCOME OF MATCHED UNRELATED DONOR (MUD) BONE-MARROW TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES UTILIZING MOLECULAR TYPING FOR DONOR SELECTION

      Blood
    61. STEIN AS; SNYDER D; NADEMANEE A; ODONNELL MR; TOMITA A; PARKER PM; SMITH E; SOMLO G; MARGOLIN K; MOLINA A; WONG KK; STEPAN D; LIPSETT J; NILAND J; SCHMIDT GM; FORMAN SJ
      ALLOGENEIC (ALLO) VERSUS AUTOLOGOUS (AUTO) BONE-MARROW TRANSPLANTATION (BMT) FOR AML IN 1ST COMPLETE REMISSION (CR)

      Blood
    62. SOMLO G; SNIECINSKI I; AHN C; DOROSHOW J; FORMAN S; MARGOLIN K; LEONG L; MORGAN R; RASCHKO J; HAMASAKI V; AKMAN S; MOLINA A; BRENT J; BAKER P
      PRIMING WITH G-CSF 10 MU-G KG IS MORE EFFECTIVE THAN 5 MU-G/KG IN PATIENTS (PTS) RECEIVING HIGH-DOSE CHEMOTHERAPY (HDCT) FOLLOWED BY PERIPHERAL STEM-CELL (PSC) RESCUE/

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/08/20 alle ore 11:32:49